Paik Seung Woon
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Korean J Gastroenterol. 2008 Jun;51(6):368-71.
Hepatitis C virus (HCV) is a major cause of chronic hepatitis and hepatic fibrosis worldwide. Up to 85% of individuals infected with HCV develop chronic infection, which can progress to cirrhosis and hepatocellular carcinoma. The primary goal in the treatment of HCV infection is to reduce the mortality by preventing liver-related deaths associated with the development of hepatocellular carcinoma and decompensated cirrhosis. Pegylated interferons together with ribavirin are currently the standard of care for patients with chronic hepatitis. Here, I discuss the goals of treatment, indication and treatment of chronic hepatitis C.
丙型肝炎病毒(HCV)是全球慢性肝炎和肝纤维化的主要病因。高达85%的HCV感染者会发展为慢性感染,进而可能进展为肝硬化和肝细胞癌。治疗HCV感染的主要目标是通过预防与肝细胞癌和失代偿性肝硬化发展相关的肝脏相关死亡来降低死亡率。聚乙二醇化干扰素联合利巴韦林目前是慢性肝炎患者的标准治疗方案。在此,我将讨论慢性丙型肝炎的治疗目标、适应证及治疗方法。